Status:
COMPLETED
Intervention to Reduce Misused Inhaler and Insufficient Peak Inspiratory Flow in Hospitalized COPD Patients
Lead Sponsor:
Hôpital Fribourgeois
Conditions:
COPD
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The drug treatment of chronic obstructive pulmonary disease (COPD) is mainly based on inhaled therapy. This route of administration is limited by inhaler handling errors, insufficient inspiratory flow...
Eligibility Criteria
Inclusion
- Admission to the HFR Fribourg internal medicine department
- Age greater than or equal to 18 years
- Diagnosis of COPD
- Use of an inhaler device for the treatment of COPD before admission
Exclusion
- Inability to complete initial assessment due to language problems
- Inability to complete initial assessment due to physical or mental conditions
- Patient who has already received the intervention during a previous hospitalization.
- Length of hospitalization of less than 72 hours
- Patient already included in the control period
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 24 2023
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT05207631
Start Date
March 1 2022
End Date
January 24 2023
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HFR Fribourg
Fribourg, Switzerland, 1700